Washington, United States. AFP.
The first doses of an AIDS vaccine using messenger RNA technology have been administered to humans, US biotech company Moderna and the International AIDS Vaccine Initiative announced on Thursday.
The so-called phase 1 trial will be carried out in the United States in 56 healthy adults without HIV. Despite four decades of research, scientists have yet to develop a vaccine against this disease that kills hundreds of thousands of people every year.
However, the recent successes of messenger RNA technology, which has allowed the development of covid-19 vaccines in record time, including that of Moderna, have raised hopes.
#sexy #iphone :How to fix iTunes error 3194 on iOS 5.1 (iPhone 4)?: ... an iPhone 4 and had...I need to restore... http://t.co/tBO0StQf
— iPhone Repairer Wed Mar 14 08:13:08 +0000 2012
The objective of the vaccine being tested is to stimulate the production of a certain type of antibody (bnAb), capable of acting against the numerous circulating variants of HIV, the virus that causes AIDS. The vaccine aims to educate the B cells, which are part of our immune system, to produce these antibodies.
To do this, the trial will test the injection of an initial immunogen; that is, a substance capable of eliciting an immune response, and a booster immunogen injected later. They will be delivered via messenger RNA technology.
"The production of bnAbs is widely considered a target of HIV vaccination, and this is a first step in that process," the statement said.